Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is being developed for Rett syndrome, and the company’s pipeline is centered on CNS gene therapy candidates.

−1 118,9 %

−1 115,3 %

+17,3 %

12.23

12.23

— Taysha Gene Therapies, Inc.
%
Lead clinical program100% TSHA-102 and related clinical development activities for Rett syndrome.
Pipeline gene therapy programs0% Additional AAV-based CNS gene therapy candidates in preclinical or early development.
Process development and manufacturing0% CMC, scale-up, and cGMP manufacturing support for clinical and future commercial supply.

Taysha does not sell approved products today; its direct counterparties are primarily regulators, clinical trial sites,...

  • Clinical trial patientsprimary

    Females with Rett syndrome enrolled in REVEAL Phase 1/2 studies to evaluate TSHA-102.

  • Clinical investigators and trial sitesprimary

    Hospitals and research centers that administer study drug and collect safety/efficacy data.

  • Contract manufacturerssecondary

    CMOs that produce cGMP gene therapy material for clinical trials and future supply.

  • Research collaborators and licensorssecondary

    Academic and institutional partners that provide technology, know-how, or licensed IP.

  • Future healthcare providers and payersemerging

    Specialty neurology providers and reimbursement decision-makers for any approved therapy.

The company is headquartered in the United States and conducts its development, regulatory, and financing activities...

  • •Headquartered in the United States
  • •Clinical and regulatory work is centered on FDA pathways
  • •Future commercialization would likely begin in the U.S.
  • •Potential expansion could include foreign regulatory markets

Taysha’s strategy is to advance TSHA-102 through clinical development and regulatory review while building the...

01
Advance TSHA-102 in Rett syndromeshort-term

The company is highly dependent on its lead clinical program for value creation.

02
Strengthen regulatory and clinical capabilitiesshort-term

Later-stage development and BLA preparation require capabilities the company has not yet fully executed at scale.

03
Build manufacturing and commercialization readinessmedium-term

Gene therapy programs require specialized CMC, supply chain, and launch infrastructure before approval.

04
Expand the pipeline beyond TSHA-102medium-term

A broader portfolio can reduce single-asset dependence and create additional development optionality.

Taysha is exposed to the high failure rate of clinical-stage biotechnology, where early signals may not translate into...

critical

Clinical development failure

TSHA-102 must show durable safety and efficacy in later-stage studies to support approval.

Scope
Lead program TSHA-102
Materiality
high
critical

Single-asset concentration

The company is substantially dependent on one clinical candidate for value creation.

Scope
TSHA-102
Materiality
high
high

Regulatory delay or rejection

The company has limited experience with pivotal trials and BLA submissions, increasing execution risk.

Scope
FDA and foreign regulatory pathways
Materiality
high
high

Manufacturing and CMC execution

AAV gene therapies require specialized process development, scale-up, and quality control.

Scope
cGMP supply and future commercial manufacturing
Materiality
high
high

Financing and dilution risk

As a pre-revenue biotech, continued development depends on external capital and access to markets.

Scope
Operating runway and future funding needs
Materiality
high
Research and development expense recognition
Affects operating loss and cash burn
Stock-based compensation
Affects reported operating expenses and net loss
Asset impairment
Can create non-cash charges in operating results
Deferred revenue
Can affect revenue timing and operating cash flow

Neurogene Inc.

NGNE · Pharmaceutical Preparations

Tenaya Therapeutics, Inc.

TNYA · Biological Products, (No Diagnostic Substances)

ANAVEX LIFE SCIENCES CORP.

AVXL · Biological Products, (No Diagnostic Substances)

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

: 29/04/2026